Abstract 141P
Background
To investigate the correlation between different expression of CDK5RAP3 and UFM1 and the long-term survival of patients undergoing radical gastrectomy.
Methods
The expression of CDK5RAP3 and UFM1 in cancer and adjacent tissues of gastric cancer patients were detected, and their relationship with clinical pathological parameters and long-term prognosis were analyzed.
Results
Low expression of CDK5RAP3 was detected in 102 patients (78.5%), and UFM1 expression was low in 99 patients (76.2%), and the expression of the two was significantly positively correlated. Based on the co-expression of CDK5RAP3 and UFM1, we found that the low expression of CDK5RAP3 and UFM1 was closely related to the depth of invasion (P = 0.041), lymph node metastasis (p = 0.006), and TNM stage (P = 0.000). In Kaplan-Meier analysis, the prognosis of patients with low expression of CDK5RAP3 and UFM1 was significantly poorer than that of patients with high expression of CDK5RAP3 or UFM1 (p = 0.005), and could be used as an independent risk factor for the prognosis of the entire group of patients. The co-expression of CDK5RAP3 and UFM1 had the largest area under the ROC curve, and the patients’ long-term prognosis was better than the TNM stage alone, and has statistical significance (p <0.05).
Conclusions
The expressions of CDK5RAP3 and UFM1 are significantly reduced in gastric cancer tissues. The co-expression of CDK5RAP3 and UFM1 is an independent prognostic factor for gastric cancer. Combining the expression of the two can provide a more accurate prognostic model for predicting the overall survival of gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session